Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.44 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | EPOR | P19235 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429080 | 0.86 | MEN1 (0.46) | BCHELTA4HEPORRAB9ASMN1; SMN2 | |
| SCHEMBL16429181 | 0.85 | MC4R (0.39) | LTA4HMMP2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL2403063 | 0.81 | MC4R (0.43) | MEN1KMT2AMMP2CHRNA1CHRNG | |
| SCHEMBL18223036 | 0.81 | CA12 (0.43) | SMN1; SMN2MEN1KMT2AMMP2 | |
| SCHEMBL16264603 | 0.81 | BCHE (0.59) | BCHE | |
| SCHEMBL16428940 | 0.81 | MMP2 (0.40) | MMP2CHRNA1CHRNGCHRNB1CHRND | |
| SCHEMBL16429433 | 0.80 | CHRNA1 (0.42) | MMP2CHRNA1CHRNGCHRNB1CHRND | |
| Hydrochloric Acid SCHEMBL16247087 | 0.80 | MC4R (0.42) | SMN1; SMN2MMP2CHRNA1CHRNGCHRNB1 | |
| SCHEMBL16429184 | 0.80 | ALDH1A1 (0.38) | KMT2A | |
| Hydrochloric Acid SCHEMBL16246761 | 0.80 | MMP2 (0.40) | MMP2CHRNA1CHRNGCHRNB1CHRND |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10440955-B2 | Methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2018-05-10 | — | — | US | disclosed |
| US-9839219-B2 | Compositions comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | CURZA GLOBAL, LLC | 2016-11-17 | — | — | US | disclosed |
| US-9439433-B2 | Compositions and methods comprising a biocidal polyamine | CURZA GLOBAL, LLC (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | THE UNIVERSITY OF UTAH | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160330962-A1 | COMPOSITIONS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMS, SMOX | BCHE 589/4885LTA4H 2604/4885EPOR 4245/4885 |
| US-10440955-B2 | Methods comprising a biocidal polyamine | SRM, SMOX, SMS | BCHE 519/4885LTA4H 2345/4885EPOR 4099/4885 |
| US-20180125070-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | BCHE 475/4885LTA4H 2411/4885EPOR 4156/4885 |
| US-20150038512-A1 | COMPOSITIONS AND METHODS COMPRISING A BIOCIDAL POLYAMINE | SRM, SMOX, SMS | BCHE 475/4885LTA4H 2411/4885EPOR 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.